Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Nhwa Starts China Trial of Novel IV Opioid Analgesic

Jiangsu Nhwa Pharma has enrolled the first patient in a Phase III trial for Olinvyk (oliceridine) injection, a novel IV analgesic. Nhwa in-licensed China rights to the painkiller from Trevena, a  Philadelphia company. Olinvyk, which was approved in the US in 2020, is an intravenous opioid analgesic indicated for acute pain that is not treated by alternative drugs. Founded in 1978, Nhwa is a China pharma focused exclusively on CNS drugs. Its products address anesthesiology, psychiatry and neurology needs. More details.... Stock Symbols: (SHZ: 2262) (NSDQ: TRVN) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.